About this trial
Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data. Cancer patients face a 4-7 times higher risk of thrombosis compared to non-cancer individuals. Certain cancer treatments, such as chemotherapy and targeted therapy, elevate the likelihood of venous thromboembolism (VTE). Cancer patients with VTE exhibit a significantly higher hazard ratio (H.R.) of 3.4 compared to those without VTE.
This study aims to explore three main topics: (1) Comparing the differences and similarities of leukocyte populations between cancer-associated thrombosis (CAT) and venous thromboembolism (VTE). (2) Characterizing the factors contributing to increased incidence of cancer-associated thrombosis (CAT), with the hypothesis that circulating tumor microemboli (CTM) may express more thrombosis-related proteins than CTCs. (3) Understanding the effects of aspirin or NOACs on cancer-associated thrombosis and CTM formation.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
age≧18
participants (1)participants without cancer: without cancer in five years (2)participants with cancer:pathology reveal have malignant tumor
patients who underwent catheter-based thrombectomy
agree do the thrombectomy
Disqualifiers
participants without cancer (1).shock (2).severe sepsis (3).with cancer in five years
participants with cancer (1).shock (2).severe sepsis
Trial population
patients who underwent catheter-based thrombectomy
Trial design
Case-only
Cross-sectional
Treatments tested in this trial
CTCs/CTMs culture
Procedure/SurgeryCollect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture
Treatment groups
Trial outcomes
Primary outcomes
cell culture
cancer-specific surface markers
RNA-seq
DNA/RNA extraction of sorted cells as instruments' maneuvers and do the RNA-seq
Sponsors and contacts
Click on the lead sponsor to view all of their trials.